A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate covid-19

HIGHLIGHTS

• who: Adeniyi Olagunju from the Miguel Hernu00e1ndez of Elche, Spain have published the Article: A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19, in the Journal: (JOURNAL) of November/25,/2020
• what: Multivariable Cox proportional hazard regression analysis was conducted to assess the differentials in time to improvement.
• how: The NACOVID trial was conducted in an inpatient setting with participants enrolled after diagnosis and within 48 h of admission. Leicestershire United Kingdom) and saliva samples were collected to determine the trough concentration of tizoxanide the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.